Siste måned
30 dager
0
NETTO POSISJON (NOK)
Handler
0
Kjøp
0
Salg
0
6 måneder
180 dager
+1 647 954
NETTO POSISJON (NOK)
Handler
10
Kjøp
1 647 954
Salg
0
Historikk
ℹ️ Om innsidehandel
Primærinnsidere er personer med ledelsesansvar og deres nærstående. Meldeplikt inntrer når transaksjoner når EUR 5 000 i et kalenderår.
Meldefrist: umiddelbart, senest tre virkedager. Handelsforbud 30 dager før pliktig finansiell rapportering.
Transaksjoner
Mer info 👉
| Dato | Innsider | Antall | Pris | Verdi |
|---|---|---|---|---|
| 07.10.2025 |
Philip Slätis
Commercial Director RX & International
|
3 422 | 21.50 | 73 573 |
| 07.10.2025 |
Astrid T. Bratvedt
Chief Scientific Officer
via Tranbergkollen Invest AS
|
25 000 | 21.50 | 537 500 |
| 07.10.2025 |
Jostein Davidsen
Chairperson of the board of directors
|
17 116 | 21.50 | 367 994 |
| 07.10.2025 |
Morten Jurs
Board member
via Jurs AS
|
7 851 | 21.50 | 168 796 |
| 07.10.2025 |
Kathrine Elisabeth Gamborg Andreassen
CEO
via Soleglad Invest AS
|
23 260 | 21.50 | 500 090 |
| 03.10.2025 |
Philip Slätis
Commercial Director RX & International
|
3 422 | 21.50 | 73 573 |
| 03.10.2025 |
Astrid T. Bratvedt
Chief Scientific Officer
via Tranbergkollen Invest AS
|
25 000 | 21.50 | 537 500 |
| 03.10.2025 |
Jostein Davidsen
Chairperson of the board of directors
|
17 116 | 21.50 | 367 994 |
| 03.10.2025 |
Morten Jurs
Board member
via Jurs AS
|
7 851 | 21.50 | 168 796 |
| 03.10.2025 |
Kathrine Elisabeth Gamborg Andreassen
CEO
via Soleglad Invest AS
|
23 260 | 21.50 | 500 090 |
Pressemeldinger
| Dato | Melding |
|---|---|
| 07.10.2025 |
Navamedic ASA: Allocation of shares in the rights issue to primary insiders and their close associates
Oslo, 7 October 2025: Reference is made to the stock exchange announcement
published by Navamedic ASA (the "Company") earlier today regarding the fina...
|
| 03.10.2025 |
Navamedic ASA: Mandatory notification of trades by primary insiders and their close associates
Oslo, 3 October 2025: Reference is made to the stock exchange announcement
published by Navamedic ASA (the "Company") on 22 September 2025, regarding ...
|